ProQR Therapeutics N.V.

PRQR | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.88

+$0.02 (+1.08%)

Sep 22, 2026, 12:35 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.08%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $198.37M

1D Range

1.84 1.91

52W Range

1.33 3.10

Valuation (TTM)

PE -3.99

PB 2.16

EV/EBITDA -1.79

Valuation (NTM)

Forward PE N/A

Forward PEG -0.25

Price Target $3

Cash Flow

FCF Yield -29.4%

SBC Adj. FCF Yield -31.6%

SBC Impact -7.5%

Margins

Gross Margin 92.3%

Operating Margin -232.7%

FCF Margin -270.8%

Growth (CAGR)

Revenue 3Y | 5Y 66.3% | 95.3%

Dil EPS 3Y | 5Y -17.7% | 23.0%

FCF 3Y | 5Y -16.4% | -18.6%

Returns

ROA -31.8%

ROE -68.4%

ROIC -41.9%

Financial Health

Net Cash

€112.58M ($128.58M)

Current Ratio 3.49

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes tw...

Sector Healthcare

Industry Biotechnology

Employees 166

IPO Date Sep 17, 2014

Website www.proqr.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+59.57%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞